EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pragmaticism in Cancer Clinical Trials

Kamya Sankar, Mary W Redman, Konstantin H Dragnev, Brian S Henick, Wade T Iams, Charles D Blanke, Roy S Herbst, Jhanelle E Gray, Karen L Reckamp iD

American Society of Clinical Oncology Educational Book · 2024-06 · 44 (3)

DOI: 10.1200/edbk_100040 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2024-06. Verfasst von Kamya Sankar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cedars-Sinai Medical Center, Los Angeles, CA. Hauptthemen laut MEDLINE: Neoplasms, Clinical Trials as Topic. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials are essential for advancing oncology treatment strategies and have contributed significantly to the decline in cancer mortality rates over the past decades. Traditional explanatory trials, focused on establishing intervention efficacy in ideal settings, often lack generalizability and may not reflect real-world patient care scenarios. Furthermore, increasing complexity in cancer clinical trial design has led to challenges such as protocol deviations, slow enrollment leading to lengthened durations of trial, and escalating costs. By contrast, pragmatic trials aim to assess intervention effectiveness in more representative patient populations under routine clinical conditions. Here, we review the principles, methodologies, challenges, and advantages of incorporating pragmatic features (PFs) into cancer clinical trials. We illustrate the application of pragmatic trial designs in oncology and discuss the QUASAR collaborative, TAPUR study, and the ongoing PRAGMATICA-LUNG trial. Although not all oncology trials may be amenable to adopting fully pragmatic designs, integration of PFs when feasible will enhance trial generalizability and real-world applicability. Project Pragmatica and similar initiatives advocate for the integration of real-world practice with clinical trials, fostering a nuanced approach to oncology research that balances efficacy and effectiveness assessments, ultimately with a goal of improving patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsClinical Trials as TopicHumansResearch DesignPragmatic Clinical Trials as TopicMedical Oncology

Autor:innen und Institutionen

  • Cedars-Sinai Medical Center, Los Angeles, CA.
  • SWOG Statistics and Data Management Center, Seattle, WA.
  • Fred Hutchinson Cancer Center, Seattle, WA.
  • Dartmouth Hitchcock Medical Center, Lebanon, NH.
  • Columbia University/Herbert Irving Comprehensive Cancer Center, New York, NY.
  • Vanderbilt University Medical Center, Nashville, TN.

ORCID-Profile: Karen L Reckamp

Förderung

  • NCI NIH HHS

Zitieren

APA

Sankar, K., Redman, M. W., Dragnev, K. H., Henick, B. S., Iams, W. T., Blanke, C. D., Herbst, R. S., Gray, J. E., & Reckamp, K. L. (2024). Pragmaticism in Cancer Clinical Trials. American Society of Clinical Oncology Educational Book, 44(3). https://doi.org/10.1200/edbk_100040

Vancouver

Sankar K, Redman MW, Dragnev KH, Henick BS, Iams WT, Blanke CD, et al. Pragmaticism in Cancer Clinical Trials. American Society of Clinical Oncology Educational Book. 2024;44(3). doi:10.1200/edbk_100040

BibTeX
@article{Sankar2024,
  author = {Sankar, Kamya and Redman, Mary W and Dragnev, Konstantin H and Henick, Brian S and Iams, Wade T and Blanke, Charles D and Herbst, Roy S and Gray, Jhanelle E and Reckamp, Karen L},
  title = {Pragmaticism in Cancer Clinical Trials},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2024},
  volume = {44},
  number = {3},
  doi = {10.1200/edbk_100040}
}
Kostenlos starten →